ClinicalTrials.gg
Not yet recruitingNCT07941492Updated Nov 17, 2026

A Trial of FHD-286 Plus Mosunetuzumab in Previously Treated Follicular Lymphoma

A Phase 1 interventional study of Mosunetuzumab and FHD-286 in Follicular Lymphoma, sponsored by Weill Medical College of Cornell University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Weill Medical College of Cornell University · Phase 1, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,187 studies in Lymphoma, Follicular with a site in United States — 129 open to participants now, 218 under way, 20 of them phase 3. Lymphoma, Follicular · United States.

Planned enrollment
723rd of 1,017
22 · median 38
Started
2026
with 27 others
Phase 1
365 of 1,187
37 open now
Primary completion
2031-12
later than 201 of 217 live
Registered
1,187th of 1,187
by date

Among the 1,187 studies in Lymphoma, Follicular with a site in United States, this one is the 723rd largest by planned enrollment of the 1,017 interventional ones that give a count, is one of 28 that started in 2026, is one of 365 in phase 1, reaches primary completion later than 201 of the 217 other live ones, and was the 1,187th registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

129 of the 1,187 studies in Lymphoma, Follicular with a site in United States are open now. Recruiting first, the newest first:

124 more — sign in →

All 129 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,187 studies in Lymphoma, Follicular with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if FHD-286 in combination with mosunetuzumab is safe and tolerable for treating adults with previously treated relapsed/refractory follicular lymphoma. It will also evaluate how well the combination works and how it affects cancer-related molecular and immune markers.The main questions it aims to answer are:

  • What is the maximum tolerated dose of FHD-286 when given in combination with mosunetuzumab?
  • Is the combination of FHD-286 and mosunetuzumab safe and tolerable?
  • How many participants have a response to treatment, and how long does the treatment control the disease?
  • How does treatment affect circulating tumor DNA (ctDNA), immune responses, and molecular markers, including BAF complex mutational status?

Researchers will evaluate FHD-286 in combination with mosunetuzumab in participants with relapsed or refractory follicular lymphoma to assess safety, tolerability, and preliminary anti-tumor activity.

Read the detailed description

Follicular lymphoma (FL) which has relapsed following initial therapy is difficult to treat and carries significant associated morbidity. Cellular therapy, which includes chimeric antigen receptor (CAR) T cell therapy and bispecific antibody treatment, has become a cornerstone of treatment for relapsed FL, though most patients eventually experience disease relapse and durations of response (DOR) are often limited. Relapsed FL is enriched for mutations within subunits of the BAF nucleosome remodeling complex, which confer lymphoma B cells with a less differentiated, proliferative state. Inhibition of the SMARCA2/4 subunits of the BAF nucleosome remodeling complex with FHD-286, an orally dosed reversible inhibitor, alters the lymphoma B cell transcriptional program towards a more differentiated state with a decreased fitness advantage. Additionally, FHD-286 alters the T cell transcriptional profile towards a more naïve state with decreased exhaustion, which are features previously shown to correlate with improved clinical responses in patients undergoing treatment with CAR T cell therapy. The investigators hypothesize that the combination of FHD-286 and bispecific antibody in relapsed or refractory (R/R) FL will be well tolerated and will confer benefit to patients with previously treated FL over bispecific antibody alone. The investigators will conduct a phase Ib clinical trial investigating the safety and tolerability of combined FHD-286 plus mosunetuzumab, a bispecific antibody currently approved in R/R FL, in patients with previously treated FL. The primary objective will be to determine the maximum tolerated dose (MTD) of combined FHD-286 and bispecific antibody and to assess tolerability. Assessing efficacy through overall response rate (ORR) and progression free survival (PFS) will be a secondary objective. Exploratory objectives are aimed at elucidating the in vivo mechanism of action of FHD-286 on B cell and T transcriptional programs, T cell immunophenotypic changes, kinetics of changes in circulating tumor DNA (ctDNA), and assessing the relationship between combined FHD-286 and bispecific antibody efficacy with BAF complex mutational status.

03

Conditions studied

  • Follicular Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of FL
  • FL meeting criteria for initiation of systemic therapy per treating investigator and institutional standards
  • Eligible for SOC mosunetuzumab, which is currently FDA approved in FL after at least two
  • Age ≥ 18 years
  • performance status ≤ 2 (Appendix A)
  • Required initial laboratory parameters:, ≥ 7 g/dL; transfusions permissible at treating physician discretion. (ANC) ≥ 1000 cells/mm3. count ≥ 75,000 cells/mm3. Calculated ≥ 45 ml/min by . Total ≤ 1.5 x . , ALT, and ALP ≤ 2.5 x ULN.

Exclusion criteria

Exclusion Criteria:

  • Infection with or hepatitis type B or C. Seropositive patients are eligible if they are negative for HBV DNA by PCR and receive concomitant antiviral therapy during treatment and for additional six months after completion of therapy.
  • Active, uncontrolled systemic fungal, bacterial or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy and/or other treatment)
  • Known or suspected central nervous system (CNS) involvement by lymphoma
  • Active treatment or being within two years of active treatment for a second , excluding non-melanomatous skin cancer.
  • Any grade 3 or greater baseline AE.
  • Ongoing treatment with a moderate or strong inhibitor. These include, but are not limited to medications as follows. An additional list of prohibited medications is listed in Appendix E.
  • \< 6 months
  • Decompensated cardiac disease
  • Prolonged , defined as a corrected QT interval (QTc) using Fridericia's formula (QTcF) > 470 msec
  • Major surgery within the preceding four months
  • Ongoing treatment with equivalent to > 20mg prednisone daily
  • Evidence of transformation of FL
  • Active
  • History of bone marrow transplant
  • Pregnant or breastfeeding
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    Dose Level -1

    2.5mg FHD-286 daily

    Drug: Mosunetuzumab · Drug: FHD-286

  • Experimental
    Dose Level 0

    5mg FHD-286 daily

    Drug: Mosunetuzumab · Drug: FHD-286

  • Experimental
    Dose level +1

    7.5mg FHD-286 daily

    Drug: Mosunetuzumab · Drug: FHD-286

  • Experimental
    Dose Level +2

    10mg FHD-286 daily

    Drug: Mosunetuzumab · Drug: FHD-286

Interventions

  • DrugMosunetuzumab

    will be administered per SOC procedures

  • DrugFHD-286

    will be administered in 2.5mg, 5mg, 7.5mg, or 10mg doses, depending on dose level, by oral tablet

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD)

    Time frame: up to 2 years

Secondary outcomes

  1. Overall response rate (ORR)

    Time frame: up to 2 years

  2. Complete response rate (CR)

    Time frame: up to 2 years

  3. Rates of adverse events

    Time frame: up to 6 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2031, 61 months later.

Of 89 non-industry phase 1 interventional studies under Lymphoma, Follicular, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 99. This study's planned 61 months is close to that.

Counting every sponsor, half of 173 studies reached it within 51 months; a quarter within 30 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartEst.
Nov 2026
Primary completionEst.
Dec 2031
CompletionEst.
Dec 2031
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941492
Collaborators
Foghorn Therapeutics Inc., Follicular Lymphoma Foundation
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Nov 2026 (estimated)
Primary completion
Dec 2031 (estimated)
Completion
Dec 2031 (estimated)
Last update
Nov 17, 2026

Study contacts

Simone Morris, RN
Contact
wem9038@med.cornell.edu
212-746-1362
Brittany Hobbie, MPH
Contact
brh4008@med.cornell.edu
Richard Furman, MD
principal investigator · Weill Medical College of Cornell University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion